Plasma Aβ Test Wins Approval—Are p-Tau Tests Far Behind?
Regulators in the U.S. and Europe have certified a mass-spectrometry-based blood test for amyloid-β. Plasma phospho-tau markers are poised to come next.
ALL NEWS
5 RESULTS
Sort By:
- Most Recent
- Most Commented
Getting Under Your Skin: Does Vitiligo Elevate Dementia Risk?
In a retrospective study, people with vitiligo had 12 times the risk of developing Alzheimer’s disease than did healthy controls. Why is that?
In Phase 2 Trial, Neflamapimod Aids Cognition in Lewy Body Dementia
After missing primary endpoints in Alzheimer’s trials, this p38 MAPKa inhibitor gained some traction in a test in people with DLB.
Learning Troubles Spied by Smartphone Track with Biomarkers
Remote assessments on a smartphone closely matched tests taken in the clinic. They also may detect slip-ups in learning—an earlier cognitive deficit that arises in preclinical AD.
Aducanumab Still Needs to Prove Itself, Researchers Say
While the FDA weighs aducanumab’s marketing license application, Alzheimer’s researchers agree that the agency’s own statistician correctly assessed the data as weak. Most prefer that one more trial be done.
Current Filters
- Date Range : Nov 2020 to Nov 2020 x